GS
ESPR

GTS Securities’s Esperion Therapeutics ESPR Stock Holding History

GTS Securities’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-105,500
Closed -$174K – 2154
2024
Q3 		$174K Sell
105,500
-18,900
-15% -$38.2K ﹤0.01% 3695
2024
Q2 		$276K Buy
124,400
+108,500
+682% +$255K ﹤0.01% 3198
2024
Q1 		$42.6K Sell
15,900
-14,800
-48% -$36K ﹤0.01% 3644
2023
Q4 		$91.8K Buy
+30,700
New +$39.8K ﹤0.01% 3764

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

GTS Securities's ESPR Position: Q2 2026 in Review

GTS Securities opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 271,769 shares worth $859K. The stake represents 0.02% of the portfolio and ranks #504 among its holdings. This is a return to the name: GTS Securities previously reported a position in ESPR as recently as Q3 2024.

GTS Securities first reported a position in ESPR in Q3 2023 and has held it in 6 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • GTS Securities held 271,769 shares of Esperion Therapeutics worth $859K as of Q2 2026.
  • Esperion Therapeutics was a new GTS Securities position in Q2 2026.
  • Esperion Therapeutics made up 0.02% of GTS Securities's portfolio in Q2 2026, its #504 holding.
  • GTS Securities first reported a position in Esperion Therapeutics in Q3 2023 and has held it in 6 quarters since.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.